ALLMedicine™ Barrett Esophagus Center

Mar 25th, 2023 - This study fills a gap in literature by providing contemporary real-world evidence on the prevalence of patients with gastroesophageal reflux disease (GERD), Barrett esophagus (BE), and Barrett esophagus-related neoplasia (BERN) and their upper en...

Mar 23rd, 2023 - Recent studies have suggested that sleeve gastrectomy (SG) is associated with the development of Barrett esophagus (BE) even in the absence of gastroesophageal reflux disease (GERD) symptoms. The aim of this study was to assess the rates of upper ...

Mar 12th, 2023 - to review recent literature concerning long-term health issues and transitional care in esophageal atresia (EA) patients. PubMed, Scopus, Embase and Web of Science databases were screened for studies regarding EA patients aged more than or equal t...

Feb 8th, 2023 - Oesophageal carcinoma significantly contributes to the global cancer burden ranking as the sixth leading cause of global cancer-related death. Oesophageal squamous cell carcinoma (OESCC) is one of the most common type of upper gastrointestinal (UG...

Jan 23rd, 2023 - Magnetic capsule endoscopy (MACE) systems were developed over the past 5-10 years to investigate the upper GI tract, especially the stomach. The new Navicam MACE system is composed of a magnetic capsule endoscope, an external controller magnet, a ...

Mar 2nd, 2017 - Barrett esophagus (BE) is a known risk factor for the development of esophageal adenocarcinoma. Pathologists play a critical role in confirming the diagnosis of BE and BE-associated dysplasia. As these diagnoses are not always straightforward on r...

Feb 8th, 2023 - Oesophageal carcinoma significantly contributes to the global cancer burden ranking as the sixth leading cause of global cancer-related death. Oesophageal squamous cell carcinoma (OESCC) is one of the most common type of upper gastrointestinal (UG...

Jan 23rd, 2023 - Magnetic capsule endoscopy (MACE) systems were developed over the past 5-10 years to investigate the upper GI tract, especially the stomach. The new Navicam MACE system is composed of a magnetic capsule endoscope, an external controller magnet, a ...

Sep 30th, 2022 - Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer ...

Sep 21st, 2022 - Esophageal cancer is the seventh most common cancer and the sixth leading cause of cancer related death worldwide in 2020. The highest-incidence areas include Eastern and Central Asia, sub-Saharan Africa, and some South American countries, with es...

Jul 21st, 2022 - The technique of Endoscopic Mucosal Resection (EMR) is currently widely used in the US to remove precancerous or cancerous lesions confined to the mucosa of the GI tract. EMR carries lower morbidity and mortality compare to surgery, at the expense...

Jan 11th, 2023 - Undergoing bariatric surgery for severe obesity was linked to a decreased incidence of esophageal and gastric cancer and overall in-hospital mortality, a French cohort study showed. Among mostly women, the incidence rates of these cancers were 4.9...

Oct 18th, 2022 - The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 PHALCON-EE trial. Vonoprazan achieved higher ra...

Oct 13th, 2022 - Establishing courses of personalized care for patients with esophageal squamous cell carcinoma (ESCC) has paced behind management of other gastric cancers.1 However, progress has been made with immunotherapy approvals such as nivolumab (Opdivo) in...

Jun 22nd, 2022 - Roux-en-Y gastric bypass yielded slightly better weight loss at 10 years compared with laparoscopic sleeve gastrectomy, according to results from the randomized SLEEVEPASS study. Among 240 patients with obesity, estimated mean percentage excess we...

Jun 14th, 2022 - Transcript: John Marshall, MD: Hello, and welcome to this OncLive® My Treatment Approach program titled The Evolving Treatment Landscape of Esophageal Squamous Cell Carcinoma. I’m John Marshall, a professor of medicine and oncology at Georgetown ...